1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.2.1 MARKETS COVERED 15
1.2.2 YEARS CONSIDERED FOR THE STUDY 15
1.3 CURRENCY 16
1.4 LIMITATIONS 16
1.5 STAKEHOLDERS 16

2 RESEARCH METHODOLOGY 17
2.1 SECONDARY DATA 18
2.1.1 KEY DATA FROM SECONDARY SOURCES 18
2.1.2 PRIMARY DATA 19
2.1.2.1 Key data from primary sources 20
2.2 MARKET SIZE ESTIMATION 21
2.2.1 BOTTOM-UP APPROACH 21
2.2.2 TOP-DOWN APPROACH 22
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 23
2.4 ASSUMPTIONS FOR THE STUDY 24

3 EXECUTIVE SUMMARY 25

4 PREMIUM INSIGHTS 28
4.1 ELISPOT AND FLUOROSPOT: MARKET OVERVIEW 28
4.2 NORTH AMERICA: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT (2018) 29
4.3 GEOGRAPHICAL SNAPSHOT OF THE ELISPOT AND FLUOROSPOT MARKET 30

5 MARKET OVERVIEW 31
5.1 INTRODUCTION 31
5.2 MARKET DYNAMICS 31
5.2.1 DRIVERS 32
5.2.1.1 Rising global incidence of chronic diseases 32
5.2.1.2 Increasing vaccine development to address the challenge of antimicrobial resistance 32
5.2.1.3 Technological advancements in ELISpot and FluoroSpot assay kits and analyzers 32
5.2.2 OPPORTUNITIES 33
5.2.2.1 Use of FluoroSpot assays for multiple-analyte detection in a single well 33
?
5.2.3 CHALLENGES 33
5.2.3.1 Availability of alternative detection technologies 33

6 ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT 34
6.1 INTRODUCTION 35
6.2 ASSAY KITS 36
6.2.1 ASSAY KITS MARKET, BY TECHNIQUE 37
6.2.1.1 ELISpot assay kits 37
6.2.1.1.1 Majority of kits available in the market are ELISpot kits 37
6.2.1.2 FluoroSpot assay kits 38
6.2.1.2.1 Increasing demand for multiple analyte detection and technological advancement are driving segmental growth 38
6.2.2 ASSAY KITS MARKET, BY UTILITY 38
6.2.2.1 Diagnostic kits 39
6.2.2.1.1 Diagnostic kits are six to eight times costlier than research kits 39
6.2.2.2 Research kits 39
6.2.2.2.1 Market growth driven by continued investment in vaccine research, clinical trials, and cancer research 39
6.2.3 ASSAY KITS MARKET, BY ANALYTE 40
6.2.3.1 T-Cell-based kits 40
6.2.3.1.1 Low concentrations of infection-released analytes necessitates use of T-cell-based kits 40
6.2.3.2 B-cell-based kits 41
6.2.3.2.1 Detection of B-cell-based antibodies is useful to study cell response post-infection/vaccination 41
6.2.3.3 Other analyte kits 41
6.3 ANALYZERS 42
6.3.1 ADOPTION OF ASSAY KITS WILL DRIVE THE USE OF ANALYZERS 42
6.4 ANCILLARY PRODUCTS 42
6.4.1 MARKET PLAYERS SUCH AS THERMO FISHER SCIENTIFIC PROVIDE ANCILLARY PRODUCTS 42

7 ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION 44
7.1 INTRODUCTION 45
7.2 DIAGNOSTIC APPLICATIONS 46
7.2.1 INFECTIOUS DISEASES 47
7.2.1.1 Infectious diseases segment to dominate the diagnostic applications market during the forecast period 47
7.2.2 TRANSPLANTS 48
7.2.2.1 Growing incidence of infections caused during transplant procedures are driving the demand for ELISpot and FluoroSpot assays 48
?
7.3 RESEARCH APPLICATIONS 49
7.3.1 VACCINE DEVELOPMENT 50
7.3.1.1 Vaccine development segment to register the highest growth rate in the forecast period 50
7.3.2 CLINICAL TRIALS 50
7.3.2.1 Growing number of clinical trials are driving the demand for ELISpot and FluoroSpot assays 50
7.3.3 CANCER RESEARCH 52
7.3.3.1 Rising global prevalence of cancer is driving the growth of the ELISpot and FluoroSpot market 52

8 ELISPOT AND FLUOROSPOT MARKET, BY END USER 53
8.1 INTRODUCTION 54
8.2 HOSPITALS & CLINICAL LABORATORIES 55
8.2.1 HOSPITALS & CLINICAL LABORATORIES TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2018 55
8.3 RESEARCH INSTITUTES 56
8.3.1 RESEARCH INSTITUTES ARE THE FASTEST-GROWING END USERS OF THE ELISPOT AND FLUOROSPOT MARKET 56
8.4 BIOPHARMACEUTICAL COMPANIES 57
8.4.1 BIOPHARMACEUTICAL COMPANIES USE ELISPOT AND FLUOROSPOT ASSAYS FOR VACCINE DEVELOPMENT, CLINICAL TRIALS, AND CANCER RESEARCH 57

9 ELISPOT AND FLUOROSPOT MARKET, BY REGION 58
9.1 INTRODUCTION 59
9.2 NORTH AMERICA 60
9.2.1 US 62
9.2.1.1 The US will continue to dominate the North American ELISpot and FluoroSpot market during the forecast period 62
9.2.2 CANADA 63
9.2.2.1 High burden of chronic diseases in the country to drive the adoption of ELISpot and FluoroSpot assays 63
9.3 EUROPE 65
9.3.1 GERMANY 67
9.3.1.1 Germany to be the fastest-growing country in the European ELISpot and FluoroSpot market 67
9.3.2 UK 69
9.3.2.1 Rising prevalence of NCDs in the UK to drive market growth 69
9.3.3 FRANCE 70
9.3.3.1 Chronic NCDs form a key cause of death in France 70
9.3.4 REST OF EUROPE 72
?
9.4 ASIA PACIFIC 74
9.4.1 CHINA 76
9.4.1.1 China’s large vaccine industry provides favorable outlook for ELISpot and FluoroSpot assays 76
9.4.2 INDIA 78
9.4.2.1 High incidence of chronic diseases and growing vaccine R&D activity will contribute to market growth 78
9.4.3 JAPAN 79
9.4.3.1 Chronic NCDs are responsible for a large chunk of deaths in Japan 79
9.4.4 REST OF ASIA PACIFIC 81
9.5 REST OF THE WORLD 82

10 COMPETITIVE LANDSCAPE 84
10.1 OVERVIEW 84
10.2 MARKET RANKING ANALYSIS, 2017 85
10.2.1 TOP PLAYERS IN RESEARCH-USE KITS MARKET 85
10.2.2 TOP PLAYERS IN ELISPOT AND FLUOROSPOT ANALYZERS MARKET 86
10.3 KEY STRATEGIES 87
10.3.1 PRODUCT LAUNCHES 87
10.3.2 EXPANSIONS 87
10.3.3 AGREEMENTS 87
10.3.4 ACQUISITIONS 88
10.3.5 PATENTS 88
10.3.6 PRODUCT APPROVAL 88

11 COMPANY PROFILES 89
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 OXFORD IMMUNOTEC 89
11.2 CELLULAR TECHNOLOGY LIMITED (CTL) 91
11.3 MABTECH AB 93
11.4 BECTON, DICKINSON AND COMPANY 94
11.5 ABCAM 96
11.6 BIO-TECHNE 98
11.7 AUTOIMMUN DIAGNOSTIKA GMBH 100
11.8 BIOTECH INVESTISSEMENT GROUP 102
11.9 LOPHIUS BIOSCIENCES GMBH 103
11.10 U-CYTECH BIOSCIENCES 104

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
?

12 APPENDIX 105
12.1 INSIGHTS OF INDUSTRY EXPERTS 105
12.2 DISCUSSION GUIDE 106
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 108
12.4 AVAILABLE CUSTOMIZATIONS 110
12.5 RELATED REPORTS 110
12.6 AUTHOR DETAILS 111